Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Vaccination affords protection from disease by activating pathogen-specific immune cells
and facilitating the development of persistent immunologic memory toward the vaccine …

Introduction Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a highly
personalized type of cancer immunotherapy. TIL-based ACT exploits naturally occurring …

Chimeric antigen receptor (CAR) T cells and natural killer (NK) cells are genetically
engineered immune cells that can detect target antigens on the surface of target cells and …

Chimeric antigen receptor T (CAR-T) cell therapy has exhibited a substantial clinical
response in hematological malignancies, including B-cell leukemia, lymphoma, and multiple …

Advances in understanding how cancer cells interact with the immune system allowed the
development of immunotherapeutic strategies, harnessing patients' immune system to fight …

Chimeric antigen receptor (CAR) T cell therapy has led to a paradigm shift in cancer
immunotherapy, but still several obstacles limit CAR T cell efficacy in cancers. Advances in …

The ability of CD8+ T cells to infiltrate solid tumors and reach cancer cells is associated with
improved patient survival and responses to immunotherapy. Thus, identifying the factors …

Colorectal cancer (CRC), a common malignant disease, has the second highest mortality
rate among all cancer types. Due to the diversity and heterogeneity of CRC, few effective …

Genetically engineered chimeric antigen receptor (CAR) T cells can cure patients with
cancers that are refractory to standard therapeutic approaches. To date, adoptive cell …